Pharmacokinetics of the new progestogens and influence of gestodene and desogestrel on ethinylestradiol metabolism.
The purpose of the present report is to summarize the most important pharmacokinetic features of the new progestogens. In addition, the question of whether or not gestodene, in comparison to desogestrel, has an influence on the pharmacokinetics of ethinylestradiol (EE2) will be addressed.
Stanczyk
F Z
FZ
Department of Obstetrics and Gynecology, University of Southern California School of Medicine, Los Angeles 90033, USA.
D017135:Desogestrel / Q000009:adverse effects* / Q000493:pharmacokinetics; D004997:Ethinyl Estradiol / Q000378:metabolism*; D005260:Female; D006801:Humans; D007700:Kinetics; D009644:Norgestrel / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D009652:Norpregnenes / Q000009:adverse effects* / Q000493:pharmacokinetics; D045167:Progesterone Congeners / Q000493:pharmacokinetics*
D009652:Norpregnenes; D045167:Progesterone Congeners; C033273:Gestodene; D009644:Norgestrel; D004997:Ethinyl Estradiol; D017135:Desogestrel; C017576:norgestimate